Bernstein said Novo Nordisk’s (NVO) recently released SOUL study results for Rybelsus in the reduction of major ...

The oral semaglutide reduced the occurrence of major adverse cardiovascular events (MACE) by 14% in patients with T2D.

In announcing the results, Novo Nordisk said Rybelsus, an oral glucagon-like peptide-1 (GLP-1) receptor agonist already ...

As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the ...

On October 21, Novo Nordisk announced positive news on the cardiovascular benefits of its oral glucagon-like peptide-1 ...

SOUL Trial Results Position Rybelsus as a Game-Changer in Diabetes and Cardiovascular Care, Poised for Expanded U.S. and E.U.

Novo Nordisk's SOUL trial reveals a 14% reduction in major cardiovascular events with oral semaglutide in patients with type ...

Novo expects to file for a label expansion for Rybelsus in the United States and the European Union around the turn of the ...

Novo Nordisk on Monday reported the oral version of its drug semaglutide reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes by 14% in a large Phase III trial.

The medicine, which Novo sells as Rybelsus, cut the risk of cardiovascular complications by 14% when added to standard therapies in people with diabetes and heart disease.

Yet another therapy with FDA accelerated approval suffers a setback; Sage’s tough year continues; Sanofi drops $326 million ...

You’ve probably heard of the semaglutide brand names Ozempic®, Wegovy, and Rybelsus. You may have even heard about affordable options like compounded semaglutide.